Genetic and epigenetic inactivation of TNFRSFI0C in human prostate cancer

Prostate

Volumn 69, Issue 3, 2009, Pages 327-335

  Cheng, Yu ^a   Kim, Jin Woo ^a   Liu, Wennuan ^a   Dunn, Thomas A ^b   Luo, Jun ^b   Loza, Matthew J ^a   Kim, Seong Tae ^a   Zheng, Siqun Lilly ^a   Xu, Jianfeng ^a   Isaacs, William B ^b,c   Chang, Bao Li ^a,d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d Center for Human Genomics   (United States)

Author keywords

CpG islands; Promoter methylation; Somatic copy number alterations

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; DEOXYCYTIDINE; MESSENGER RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TNFRSF10C PROTEIN, HUMAN; TUMOR NECROSIS FACTOR DECOY RECEPTOR;

ARTICLE; BACTERIAL GENE; CANCER GENETICS; CELL DEGENERATION; CELL LINE; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL MOTION; CHROMOSOME DELETION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORRELATION ANALYSIS; CPG ISLAND; DEMETHYLATION; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENOME; HEMIZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; TRANSCRIPTION INITIATION; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMOSOME DELETION; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 60849121725     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20882     Document Type: Article

References (32)

1. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
2. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies. Prostate 2007;67(7):692-700.
3. Chang BL, Liu W, Sun J, Dimitrov L, Li T, Turner AR, Zheng SL, Isaacs WB, Xu J. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Cancer Res 2007;67(9):4098-4103.
4. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, Knowles M, Selby PJ. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66:2000-2011.
5. Peng D, Ren CP, Yi HM, Zhou L, Yang XY, Li H, Yao KT. Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin 2006;38:349-355.
6. Tokumaru Y, Nomoto S, Jeronimo C, Henrique R, Harden S, Trink B, Sidransky D. Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene 2003;22:6954-6958.
7. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005;65:10692-10699.
8. Yi HM, Li H, Peng D, Zhang HJ, Wang L, Zhao M, Yao KT, Ren CP. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res 2006;16:261-272.
9. Takada H, Imoto I, Tsuda H, Nakanishi Y, Sakakura C, Mitsufuji S, Hirohashi S, Inazawa J. Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene 2006;25:6554-6562.
10. Chughtai SA, Crundwell MC, Cruickshank NR, Affie E, Armstrong S, Knowles MA, Takle LA, Kuo M, Khan N, Phillips SM, Neoptolemos JP, Morton DG. Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. Oncogene 1999;18(3):657-665.
11. Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999;59(8):1973-1979.
12. Chain H, MacDonald JW, Vessella RL, Washburn JG, Quinn JE, Odman A, Rubin MA, Macoska JA. Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes Cancer 2003;37(3):306-313.
13. Charafe-Jauffret E, Moulin JF, Ginestier C, Bechlian D, Conte N, Geneix J, Adélaïde J, Noguchi T, Hassoun J, Jacquemier J, Birnbaum D. Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells. Int J Oncol 2002;21(5):989-996.
14. Adams J, Williams SV, Aveyard JS, Knowles MA. Loss of heterozygosity analysis and DNA copy number measurement on 8p in bladder cancer reveals two mechanisms of allelic loss. Cancer Res 2005;65(1):66-75.
15. Ono K, Miyakawa A, Fukuda M, Shiiba M, Uzawa K, Watanabe T, Miya T, Yokoe H, Imai Y, Tanzawa H. Allelic loss on the short arm of chromosome 8 in oral squamous cell carcinoma. Oncol Rep 1999;6(4):785-789.
16. Van Noesel MM, van Bezouw S, Salomons GS, Voûte PA, Pieters R, Baylin SB, Herman JG, Versteeg R. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 2002;62(7): 2157-2161.
17. Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, Chaudhary PM, Gazdar AF. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 2004;109(5):786-792.
18. Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B, Favrot MC, Plantaz D. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 2006;166(1):74-81.
19. Hornstein M, Hoffmann MJ, Alexa A, Yamanaka M, Müller M, Jung V, Rahnenführer J, Schulz WA. Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics 5(2):123-136.
20. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-3873.
21. Warnecke PM, Stirzaker C, Song J, Grunau C, Melki JR, Clark SJ. Identification and resolution of artifacts in bisulfite sequencing. Methods 2002;27(2):101-107.
22. Dunn T, Chen S, Faith D, Hicks J, Platz E, Chen Y, Ewing C, Sauvageot J, Isaacs W, De Marzo A, Luo J. A novel role of myosin VI in human prostate cancer. Am J Pathol 2006;169(5):1843-1854.
23. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques 2005;39(1):75-85.
24. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005;5(1):54.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.
26. Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, Turner AR, Kim JW, Meyers DA, Zheng SL, Isaacs WB, Xu J. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer 2006; 45:1018-1032.
27. Liu W, Chang BL, Cramer S, Koty PP, Li T, Sun J, Turner AR, Von Kap-Herr C, Bobby P, Rao J, Zheng SL, Isaacs WB, Xu J. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res 2007;13:5028-5033.
28. Suzuki M, Shigematsu H, Shivapurkar N, Reddy J, Miyajima K, Takahashi T, Gazdar AF, Frenkel EP. Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett 2006;242(2):222-230.
29. Murphy TM, Perry AS, Lawler M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer 2008;15(1):11-25.
30. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-B pathway. Immunity 1997;7:821-830.
31. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-B. Immunity 1997;7:831-836.
32. Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-B/IB proteins and cancer. Oncogene 1996;13:1367-1378.